Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro

Journal of Cellular Physiology

Volumn 185, Issue 1, 2000, Pages 126-134

  Porta, Camillo ^a   Danova, Marco ^a   Orengo, Anna Maria ^b   Ferrini, Silvano ^b   Moroni, Mauro ^c   Gaggero, Alessia ^b   Libener, Roberta ^d   Betta, Pier Giorgio ^d   Ferrari, Silvia ^a   Procopio, Antonio ^e   Strizzi, Luigi ^e   Mutti, Luciano ^f,g  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d C Arrigo Children's Hospital   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f IRCCS   (Italy)

^g Local Health Authority 11   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CALCIUM TRANSPORT; CASE REPORT; CELL CYCLE; CELL DEATH; CELL KINETICS; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOMODULATION; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; CELL DIVISION; HUMANS; INTERLEUKIN-2; MESOTHELIOMA; TUMOR CELLS, CULTURED;

EID: 0033846746     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4652(200010)185:1<126::AID-JCP12>3.0.CO;2-2     Document Type: Article

References (32)

1. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. A phase II study
2. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
3. Verapamil inhibits to different extents agonist-induced Ca(++) transients in human tumor cells and in vitro tumor cell growth
4. Effectiveness of very-low doses of immunotherapy in advanced renal cell cancer
5. Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro
6. Calcium influx in induced differentiation of murine erytroleukemia cells
7. Intrapleural administration of interleukin-2 in pleural mesothelioma: A phase I-II study
8. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
9. Malignant mesothelioma: Review of 4,710 pubished cases
10. Recombinant interleukin-2-based treatment for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
11. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients
12. The induction of immune responses to murine malignant mesothelioma by IL-2 gene-transfer
13. Expression of adhesion molecules relevant to leukocyte migration on the microvilli of liver peritoneal mesothelial cells
14. Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions
15. Pleural malignant mesothelioma and environmental asbestos exposure in Casale Monferrato, Piedmont. Preliminary analysis of a case-control study
16. Platelet agonists induce CaP(2+) transients in tumor cells by opening distinct receptor-operated channels: An effect unrelated to the presence of classical multi-drug resistance phenotype
17. Primary human mesothelioma cells express class-II MHC, ICAM-1 and B7.2 and can present recall antigens to autologous blood lymphocytes
18. In situ apoptotic cell labelling by the TUNEL method: Improvement and evaluation on cell preparations
19. Interleukin-2: Solid tumor therapy
20. Establishment of four new mesothelioma cell lines: Characterization by ultrastructural anf immunophenotypic analysis
21. Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer
22. Platelet agonists and calcium homeostasis in endothelial cells: Possible role in the interaction of endothelium with hemostatic system
23. Phenotypic mapping of human mesothelial cells
24. Effect of different platelet agonists on intracellular free Ca(++) concentrations in human tumor cells: Possible role in tumor growth
25. In vitro predictors of therapeutic response in melanoma patients receiving tumorinfiltrating lymphocytes and interleukin-2
26. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP
27. Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells
28. Interleukin 2 and its receptors: Recent advances and new immunological functions
29. The eosinophil granule proteins in serum, but not the oxidative matabolism of the blood eosinophils, are increased in cancer
30. Receptors for interleukin-2 on human squamous cell carcinoma cell lines and tumor in situ
31. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
32. Expression of interleukin-2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin-2